Urinary retention in female OAB after intravesical Botox injection: who is really at risk?

Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study

(2016) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Can botox improve night-time overactive bladder symptoms in women?

(2016) Pawel Miotla et al.   NEUROUROLOGY AND URODYNAMICS

Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms

(2016) T. A. T. Marcelissen et al.   WORLD JOURNAL OF UROLOGY

Patient preferences for treating refractory overactive bladder in the UK

(2015) Hashim Hashim et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center

(2015) Yuan-Hong Jiang et al.   NEUROUROLOGY AND URODYNAMICS

Women’s perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment

(2014) Pooja Balchandra et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events

(2014) N. F. Davis et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Chapter 6: Practical aspects of administration of onabotulinumtoxinA

(2014) Eric Rovner   NEUROUROLOGY AND URODYNAMICS

Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome

(2014) David James Osborn et al.   NEUROUROLOGY AND URODYNAMICS

Lifetime Risk of Stress Urinary Incontinence or Pelvic Organ Prolapse Surgery

(2014) Jennifer M. Wu et al.   OBSTETRICS AND GYNECOLOGY

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

(2013) Christopher Chapple et al.   EUROPEAN UROLOGY

Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxina injection in patients with refractory detrusor overactivity

(2013) Chung-Cheng Wang et al.   NEUROUROLOGY AND URODYNAMICS

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline

(2012) E. Ann Gormley et al.   JOURNAL OF UROLOGY

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Increased Risk of Large Post-Void Residual Urine and Decreased Long-Term Success Rate After Intravesical OnabotulinumtoxinA Injection for Refractory Idiopathic Detrusor Overactivity

(2012) Chun-Hou Liao et al.   JOURNAL OF UROLOGY

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

(2010) Roger Dmochowski et al.   JOURNAL OF UROLOGY

An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction

(2009) Bernard T. Haylen et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL